ACH

Business Context and Reporting Period

Company: Owens & Minor, Inc. (Note: Input metadata referenced "Accendra Health Inc," but the filing text is for Owens & Minor, Inc.)
Reporting Period: Year ended December 31, 2003
Business Overview: Owens & Minor is the leading distributor of national name-brand medical and surgical supplies in the United States. It distributes approximately 120,000 products from over 1,000 suppliers to approximately 4,000 customers, primarily acute care hospitals and integrated healthcare networks (IHNs), which account for over 90% of net sales. The company operates 41 distribution centers nationwide and offers value-added supply chain management services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% to $4.24 billion, driven primarily by increased volume to existing customers and new business.
• Profitability: Net income rose 13% to $53.6 million. This was due to increased sales, reduced financing costs, improved productivity, and a lower effective tax rate (38.9% in 2003 vs. 39.6% in 2002), partially offset by gross margin pressure and spending on strategic initiatives.
• Margin Pressure: Gross margin decreased slightly to 10.5% from 10.6% due to competitive pricing pressures and increased sales volume with larger customers.
• Financing Costs: Net financing costs decreased significantly to $17.9 million (excluding finance charge income) from $23.4 million in 2002. This reduction was driven by the repurchase and conversion of $125.2 million of mandatorily redeemable preferred securities.
• Cash Flow: Operating cash flow improved dramatically to $94.9 million from a use of $14.3 million in 2002. The 2002 figure was negatively impacted by a reduction in accounts receivable sales under the Receivables Financing Facility.

Guidance, Outlook, and Risks

• Strategic Initiatives: Management continues to invest in strategic initiatives including OMSolutions (supply chain consulting), third-party logistics, and the MediChoice private label program. Spending on these initiatives is expected to continue in 2004.
• Capital Expenditures: Capital expenditures were $17.7 million in 2003. In 2004, the company expects to incur expenditures for the design and construction of a new corporate headquarters while reducing spending on information system upgrades.
• Outlook: Management expects competitive pricing pressure to continue. The company aims to counteract this through value-added services and supplier programs.
• Risks:
  • Customer Concentration: Sales to Novation members represented 49% of net sales, and Broadlane members represented 15%. Loss of a major customer could have a significant effect.
  • Supplier Dependence: Approximately 16% of sales were Johnson & Johnson products and 14% were Tyco International products.
  • Goodwill Impairment: Goodwill totaled $198.1 million. A decline in business volume or profitability could result in impairment.
  • Interest Rate Risk: The company has $100 million in interest rate swaps; a 100 basis point increase in rates would reduce pre-tax earnings by approximately $1.0 million annually.

Investor Verification Checklist

• Customer Concentration: Verify the stability of contracts with Novation (49% of sales) and Broadlane (15% of sales).
• Margin Trends: Monitor the impact of competitive pricing on gross margins, which have declined from 10.7% in 2001 to 10.5% in 2003.
• Debt Structure: Confirm the status of the $200 million Senior Subordinated Notes due 2011 and the $150 million revolving credit facility.
• Capital Allocation: Track the execution of the new corporate headquarters construction and the associated capital spending in 2004.
• Goodwill Valuation: Review the annual impairment testing of the $198.1 million goodwill balance under SFAS 142.